Webinars
Available On Demand
Join Trinity Life Sciences for a virtual demo where value, access and pricing experts Max Hunt and Andreia Ribeiro will demonstrate Trinity HTA Vision, our cloud-based dashboard with GenAI capabilities.It is not enough to know what the health technology assessment (HTA) decisions are and when they are made—with the landscape continually evolving, analogues and future impact cannot be judged by looking at decisions alone. Nuanced implications come from expert knowledge of countries/agencies, therapeutic areas and lifecycle stage.Discover the power of HTA…
Watch Now
Blog
Published January 17, 2025
One trend Trinity Life Sciences has observed and that was reinforced by stakeholders at ISPOR EU is the importance of evidence in healthcare decision-making. This trend was highlighted particularly in the context of joint clinical assessments (JCA) and health technology assessments (HTA). Trinity presented 11 posters at ISPOR EU, 6 of which focused on HTA and/or JCA.
JCA is an EU initiative intended to improve patient access to health technologies in Europe through a harmonized clinical HTA process. Beginning in January…
Read Now
Briefs
Joint clinical assessment (JCA) is a European Union (EU) initiative intended to improve patient access to health technologies in Europe through a harmonized clinical health technology assessment (HTA) process. From January 2025, all new oncology medicines and advanced therapy medicinal products will go through the JCA process, followed by all orphan medicinal products from 2028 and all new medicines from 2030.
The JCA process will run parallel to European Medicines Agency (EMA) regulatory evaluation and will involve submission of a…
Read Now
Briefs
The Institute for Clinical and Economic Review (ICER) is an independent, non-profit research organization dedicated to assessing the value of healthcare interventions, including diagnostics, devices, digital therapeutics and prescription drugs. Although ICER’s assessments do not represent a mandate for product funding or pricing in the U.S. in the same way as, for example, National Institute for Health and Care Excellence (NICE) assessments in the U.K., public reports on a product’s value are bound to influence discussions and negotiations between payers…
Read Now
Webinars
Available On Demand
Working at the cutting edge of pricing and market access for innovative therapies launched over the last decade, Trinity Life Sciences has seen new diseases, technologies and decision drivers emerge. These have demanded the innovation and testing of new methods and concepts for communicating value to healthcare payers.
In this webinar, we will briefly review the core, timeless principles of value communication. We will then dive into the challenges that each innovation has created for industry teams developing value strategy and value communication tools. We will review…
Watch Now
Blog
Published June 13, 2024
Trinity Life Sciences recently worked with a large global pharma company to develop a new process for creating global value dossiers (GVDs) that better met the needs of regional affiliates. Matt O’Hara, who leads Trinity’s Evidence Strategy practice, shares insights into the project with Mary Fletcher-Louis, who recently joined Trinity to head Trinity’s Value Center of Excellence.
Understanding the Challenge
The project involved reviewing the client’s 15 most recent GVDs and scoring each chapter for effectiveness, ease of use, level…
Read Now
Webinars
Available On Demand
The unprecedented availability of rich RWE data sources gives HEOR, Value and Access and Medical leaders the opportunity to be more intentional than ever before. High-quality, compelling evidence is now a necessity, not just for high-value therapies playing in the rare disease space—but also more broadly, to show reduced unmet needs, health care resource utilization (HCRU) and cost offsets.
Deep experience using industry-leading data sources, tech-enabled methodologies and therapeutic expertise allow Trinity experts to choose the right data for each…
Watch Now
